AU2022244439A1 - Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer - Google Patents

Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer Download PDF

Info

Publication number
AU2022244439A1
AU2022244439A1 AU2022244439A AU2022244439A AU2022244439A1 AU 2022244439 A1 AU2022244439 A1 AU 2022244439A1 AU 2022244439 A AU2022244439 A AU 2022244439A AU 2022244439 A AU2022244439 A AU 2022244439A AU 2022244439 A1 AU2022244439 A1 AU 2022244439A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
androgen
talazoparib
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022244439A
Other languages
English (en)
Inventor
Akos Gabor CZIBERE
Dana Ann Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Pfizer Inc
Original Assignee
Astellas Pharma Inc
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Pfizer Inc filed Critical Astellas Pharma Inc
Publication of AU2022244439A1 publication Critical patent/AU2022244439A1/en
Priority to AU2025210784A priority Critical patent/AU2025210784A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022244439A 2021-03-24 2022-03-21 Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer Abandoned AU2022244439A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025210784A AU2025210784A1 (en) 2021-03-24 2025-07-30 Combination of talazoparib and an anti-androgen for the treatment of DDR gene mutated metastatic castration-sensitive prostate cancer

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163165723P 2021-03-24 2021-03-24
US63/165,723 2021-03-24
US202163282163P 2021-11-22 2021-11-22
US63/282,163 2021-11-22
US202263317368P 2022-03-07 2022-03-07
US63/317,368 2022-03-07
PCT/IB2022/052536 WO2022200982A1 (en) 2021-03-24 2022-03-21 Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025210784A Division AU2025210784A1 (en) 2021-03-24 2025-07-30 Combination of talazoparib and an anti-androgen for the treatment of DDR gene mutated metastatic castration-sensitive prostate cancer

Publications (1)

Publication Number Publication Date
AU2022244439A1 true AU2022244439A1 (en) 2023-09-28

Family

ID=80952181

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022244439A Abandoned AU2022244439A1 (en) 2021-03-24 2022-03-21 Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
AU2025210784A Pending AU2025210784A1 (en) 2021-03-24 2025-07-30 Combination of talazoparib and an anti-androgen for the treatment of DDR gene mutated metastatic castration-sensitive prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025210784A Pending AU2025210784A1 (en) 2021-03-24 2025-07-30 Combination of talazoparib and an anti-androgen for the treatment of DDR gene mutated metastatic castration-sensitive prostate cancer

Country Status (9)

Country Link
US (1) US20240180906A1 (https=)
EP (1) EP4313034A1 (https=)
JP (1) JP2024510666A (https=)
KR (1) KR20230159510A (https=)
AU (2) AU2022244439A1 (https=)
BR (1) BR112023018906A2 (https=)
CA (1) CA3214316A1 (https=)
MX (1) MX2023011294A (https=)
WO (1) WO2022200982A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
JP4644737B2 (ja) 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
KR101456722B1 (ko) 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
NZ594741A (en) 2009-02-24 2014-03-28 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
PT2533640T (pt) 2010-02-08 2017-01-03 Medivation Technologies Inc Processos de síntese de derivados de di-hidropiridoftalazinona
NZ609490A (en) 2010-10-21 2015-06-26 Biomarin Pharm Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
TW201605814A (zh) 2013-11-07 2016-02-16 拜奧馬林製藥公司 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體
SG11201700734RA (en) 2014-07-31 2017-02-27 Medivation Technologies Inc Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
WO2018191141A1 (en) * 2017-04-13 2018-10-18 Janssen Pharmaceutica Nv Combination therapy for prostate cancer
KR20200071097A (ko) * 2017-10-13 2020-06-18 메르크 파텐트 게엠베하 Parp 억제제 및 pd-1 축 결합 길항제의 조합

Also Published As

Publication number Publication date
US20240180906A1 (en) 2024-06-06
CA3214316A1 (en) 2022-09-29
EP4313034A1 (en) 2024-02-07
MX2023011294A (es) 2023-10-05
KR20230159510A (ko) 2023-11-21
WO2022200982A1 (en) 2022-09-29
BR112023018906A2 (pt) 2023-10-10
AU2025210784A1 (en) 2025-08-21
JP2024510666A (ja) 2024-03-08

Similar Documents

Publication Publication Date Title
AU2022244439A1 (en) Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
EP3721906A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20240000783A1 (en) Combination therapy
US20250090514A1 (en) Method of treating cancer
EP4633629A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
AU2023357890A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
KR20230008783A (ko) 아비라테론 아세테이트 및 니라파립의 약제학적 제형
HK40098285A (zh) 用於治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合
CN117098535A (zh) 用于治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
WO2026078619A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078615A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2025210510A1 (en) Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor
HK40096012A (zh) 组合疗法
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
EA049014B1 (ru) Способ лечения рака

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted